ArticleEClinicalMedicine2022
The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy.
Article in EClinicalMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial.Psychological medicine · 2023Trial
- Weight maintenance after discontinuation of GLP-1 therapies.EClinicalMedicine · 2026Review
- Applicability of the New Zealand-eating behavior questionnaire to predict weight loss responses to naltrexone/bupropion: a proof-of-concept trial.Obesity pillars · 2026Article
- Voltage-gated potassium channels as important modulators of glucose-stimulated insulin secretion in pancreatic β-cells: insights from rodent and human studies.Frontiers in endocrinology · 2026Review
- Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.World journal of gastroenterology · 2025Review
- Real world efficacy of naltrexone/bupropion for weight management in obesity and after bariatric surgery.International journal of obesity (2005) · 2025Article
- Molecular Mechanisms Against Successful Weight Loss and Promising Treatment Options in Obesity.Biomedicines · 2025Review
- Appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion as treatment for obesity in primary care.Obesity pillars · 2025Review
- Trial protocol of an open-label pilot study of oralBMJ open · 2025Article
- Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: A single-centre experience.Endocrine · 2025Article
- Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity.Current obesity reports · 2025Review
- 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part II.Acta Cardiologica Sinica · 2024Article
- The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2024Article
- Detection and Intervention: Use of Continuous Glucose Monitoring in the Early Stages of Type 2 Diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- Collection on reframing obesity in health care and ending weight stigma: presenting evidence for change.EClinicalMedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extended-release (ER) naltrexone/bupropion (NB) was associated with greater weight loss than placebo in four randomized, 56-week trials. The association of NB with longer-term maintenance of weight loss remains unknown. Methods: We conducted a Findings: Our analysis included data from 10,198 particpants (NB=5412; placebo=4786). Proportions of patients with ≥5% or ≥10% weight loss maintenance were numerically higher for NB vs. placebo in all studies and time points. Differences were statistically significant for ≥5% weight loss maintenance in COR-BMOD and COR-I/-II at weeks 52 and 56 and the LIGHT study at weeks 52, 104, and 208. For ≥10% weight loss maintenance, differences were statistically significant in COR-I/COR-II at weeks 52 and 56. Interpretation: These data suggest that NB could be used as part of long-term, comprehensive weight loss and weight loss maintenance strategies. Funding: Orexigen Therapeutics, Inc. and Bausch Health Canada.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.